DrugPatentWatch Database Preview
CLINICAL TRIALS PROFILE FOR ETHINYL ESTRADIOL; NORETHINDRONE ACETATE
» See Plans and Pricing
All Clinical Trials for Ethinyl Estradiol; Norethindrone Acetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000897 | A Study to Evaluate the Effects of Different Methods of Birth Control on the Drug Actions of Zidovudine (an Anti-HIV Drug) in HIV-Positive Women and to Compare Zidovudine Metabolism in Men and Women | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | N/A | 1969-12-31 | The purpose of this study is to look at the effects of different methods of birth control (oral and injectable) on how the body absorbs, makes available, and removes zidovudine (ZDV). This study will also evaluate the differences in men and women in how the body absorbs, makes available, and removes ZDV. Past research has shown that the effectiveness of ZDV as an anti-HIV drug might be decreased in individuals who use certain methods of birth control. ZDV may also have different effects in men compared to women. |
| NCT00229996 | Medical Treatment of Endometriosis-Associated Pelvic Pain | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Phase 3 | 2004-07-01 | The Specific Aim of this project is to compare the efficacy and cost-effectiveness of continuous oral contraceptives versus leuprolide/norethindrone in the treatment of endometriosis-associated chronic pelvic pain. This comparison will be based on a randomized, double-blind, trial of women with chronic pelvic pain who have been diagnosed with endometriosis at the time of surgery within the last 3 years. We hypothesize that, over a 12-month period of postoperative treatment, the efficacy of oral contraceptives is no worse than leuprolide/norethindrone, and that treatment with oral contraceptives is more cost-effective. |
| NCT00338052 | Study of Bleeding With Extended Administration of an Oral Contraceptive | Completed | Warner Chilcott | Phase 2 | 2006-06-01 | This is an non-comparative study. There is no statistical hypothesis. The effects of extension of treatment on bleeding will be recorded and described. |
| NCT00350480 | Treatment of Non-Gestational Acute Uterine Bleeding: A Randomized Trial | Completed | Kaiser Permanente | N/A | 2003-04-01 | To determine the relative efficacy of multidose medroxyprogesterone acetate (MPA, Provera) and a multidose, monophasic combination oral contraceptive in the treatment of hemodynamically stable women with non-gestational, acute uterine bleeding. |
| NCT00391807 | Study of Safety and Efficacy of an Oral Contraceptive | Completed | Warner Chilcott | Phase 3 | 2006-11-01 | This is a non-comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding; and to assess the safety and tolerability of the product. |
| NCT00932321 | Study of Safety and Efficacy of an Oral Contraceptive | Completed | Warner Chilcott | Phase 3 | 2004-01-01 | This is a comparative study. The primary objective of the study is to assess the efficacy of a low dose oral contraceptive in the prevention of pregnancy. The secondary objectives are to assess the incidence of intracyclic bleeding of norethindrone acetate/ethinyl estradiol (NETA/EE) administered for 24 days and NETA/EE administered for 21 days; and to assess the safety and tolerability of the product. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Ethinyl Estradiol; Norethindrone Acetate
Condition Name
Clinical Trial Locations for Ethinyl Estradiol; Norethindrone Acetate
Trials by Country
Clinical Trial Progress for Ethinyl Estradiol; Norethindrone Acetate
Clinical Trial Phase
Clinical Trial Sponsors for Ethinyl Estradiol; Norethindrone Acetate
Sponsor Name
| Sponsor Name for Ethinyl Estradiol; Norethindrone Acetate | |
| Sponsor | Trials |
| Bristol-Myers Squibb | 3 |
| Warner Chilcott | 3 |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 1 |
| [disabled in preview] | 3 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
